Cargando…
TTF-1 and c-MYC-defined Phenotypes of Large Cell Neuroendocrine Carcinoma and Delta-like Protein 3 Expression for Treatment Selection
The standard treatment regimen has not yet been established for advanced pulmonary large cell neuroendocrine carcinoma (LCNEC) because of its rarity. LCNEC can be subdivided into 2 mutually exclusive molecular subgroups: STK11/KEAP1 and TP53 mutated with high neuroendocrine expression and transcript...
Autores principales: | Miyagawa-Hayashino, Aya, Okada, Satoru, Takeda-Miyata, Naoko, Takashima, Yasutoshi, Yamada, Tadaaki, Takemura, Yoshizumi, Uchino, Junji, Inoue, Masayoshi, Takayama, Koichi, Konishi, Eiichi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8132912/ https://www.ncbi.nlm.nih.gov/pubmed/33031101 http://dx.doi.org/10.1097/PAI.0000000000000875 |
Ejemplares similares
-
Multiple primary lung adenocarcinomas pre‐operatively diagnosed by discordant epidermal growth factor receptor mutations
por: Katayama, Yuki, et al.
Publicado: (2019) -
Diagnosis of unexposed tumours using endobronchial ultrasonography with a guide sheath and a thin transbronchial needle
por: Kuno, Haruka, et al.
Publicado: (2021) -
Prognostic significance of spatial immune profiles in human solid cancers
por: Tsujikawa, Takahiro, et al.
Publicado: (2020) -
A Phase II Study of S‐1 and Paclitaxel Combination Therapy as a First‐Line Treatment in Elderly Patients with Advanced Non‐Small Cell Lung Cancer
por: Yoshimura, Akihiro, et al.
Publicado: (2018) -
Analysis of Tumor Heterogeneity Through AXL Activation in Primary Resistance to EGFR Tyrosine Kinase Inhibitors
por: Nakamura, Ryota, et al.
Publicado: (2023)